Combination of Luteolin and Silibinin Has Hepatoprotective Effects on Rats' Liver Fibrosis Induced by Thioacetamide.

Introduction: A serious public health condition called liver fibrosis can cause cirrhosis, cancer, and even patient death.

Method: This study sought to determine if Luteolin [LUT] and Silibinin [SBN] could protect rats against oxidative stress and liver fibrosis caused by thioacetamide [TAA] over three weeks, as well as any potential mechanisms of action. There will be 49 adult Wistar albino rats utilized, split up into 7 groups: [G1] Negative control, [G2] Positive control, [G3] LUT+TAA, [G4] SBN+TAA, [G5] mix LUT+ SBN, [G6] LUT+SBN with TAA, [G7] LUT+SBN then TAA, and so. Liver function tests and oxidative stress markers were measured after the experiment. The liver underwent microscopic inspection. Rats given TAA treatment had significantly higher liver enzymes than control; yet, albumin [ALB], total protein [TP], superoxide dismutase [SOD], and reduced glutathione [GSH] significantly decreased.

Results: Following three weeks of TAA exposure, liver sections revealed hepatocytic damage and fibrosis. Oxidative stress, histological alterations, and alterations in liver function were all lessened in TAA rats administered with LUT, SBN, or both.

Conclusion: The combined hepatoprotective benefits of LUT and SBN prevented TAA-induced biochemical and histological alterations in rat liver, acting in concert with each other.